ClinicalTrials.gg
RecruitingNCT06862206SPEEDUpdated Nov 9, 2026

A Multicentre, Single Arm, Non-interventional, Real-world Study to Assess Demographic Characteristics and Patient Reported Outcomes in Patients With Severe Eosinophilic Asthma Treated With Benralizumab in China

An observational study in Severe Eosinophilic Asthma, sponsored by AstraZeneca. Recruiting at 36 sites in China. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2026-11-09.

Sponsored by AstraZeneca · Observational

How we know

From the registry’s dates

  • Started Jul 2025; still recruiting 1 year 4 months later.
Updated Nov 9, 2026Primary completion movedStudy completion moved+7 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
700
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 359 studies in Asthma by AstraZeneca — 19 open to participants now, 28 under way, 8 of them phase 3. Asthma · AstraZeneca.

Planned enrollment
47th of 110
700 · median 500
Started
2025
with 12 others
Observational
111 of 359
9 open now
Primary completion
2028-01
later than 16 of 27 live
Registered
339th of 359
by date

Among the 359 studies in Asthma by AstraZeneca, this one is the 47th largest by planned enrollment of the 110 observational ones that give a count, is one of 13 that started in 2025, is one of 111 observational ones, reaches primary completion later than 16 of the 27 other live ones, and was the 339th registered.

Asthma

4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.

Browse Asthma studies →

Open to participants now

19 of the 359 studies in Asthma by AstraZeneca are open now, in 12 countries. Recruiting first, the newest first:

13 more — sign in →

By country, each count listing its studies:

All 19 open studies →

Who these studies take

Of the 416 Asthma studies recruiting now, 141 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 146 take children under 18; 105 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 359 studies in Asthma by AstraZeneca, or all of them as a file.
02

Study summary

The objective of this study is to collect empirical data that elucidates the clinical profile and therapeutic efficacy of benralizumab among the patients aged 12 years and above, with severe eosinophilic asthma. The study will focus on the early treatment response, treatment outcomes and the change in asthma control of benralizumab therapy in a real-world setting in China. This study will also describe the physician-reported reasons for discontinuation and switching of benralizumab therapy.

03

Conditions studied

  • Severe Eosinophilic Asthma

Browse trials for

Keywords

  • asthma
04

Who can participate

The criteria were revised on the registry on Nov 9, 2026. See what changed

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

severe eosinophilic asthma

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Patients are eligible for inclusion only if all of the following criteria are met:

  • Aged ≥12 years at the time of signing the form.
  • Patients with severe eosinophilic asthma prescribed with benralizumab at the discretion of the clinician.
  • For the patients who had received benralizumab prior to enrolment, the interval between the Index date and the date of enrolment must \<=4 weeks;
  • ACQ-6 score within 7 days prior to index date is required.
  • Patients must have a current prescription for benralizumab with planned initiation of therapy.
  • Participating patients and/or their legally authorized representative must provide signed and dated written informed consent form prior to any study specific procedures.

Exclusion criteria

Exclusion criteria

Patients should not be enrolled if any of the following exclusion criteria are met:

  1. Patients currently participating in any other interventional clinical trial.
  2. Known history of allergy or reaction to any component of benralizumab.
  3. of any kind.
  4. Pregnant, breast-feeding or intending to become pregnant during the study period
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
700 participants (estimated)
Patient registry
No

Groups and cohorts

  • benralizumab group

    non-interventional

    Drug: benralizumab

Interventions

06

What researchers measure

Primary outcomes

  1. asthma control questionnaire

    Change from baseline in the six-item Asthma Control Questionnaire (ACQ-6) score at Week 4 after initiation of benralizumab. The ACQ-6 is a 6-item version of the Asthma Control Questionnaire. The ACQ-6 score is calculated as the mean of the 6 items and ranges from 0 to 6, with higher scores indicating worse asthma control. Change from baseline is calculated as the post-baseline ACQ-6 score at Week 4 minus the baseline ACQ-6 score.

    Time frame: Week 4

Secondary outcomes

  1. Rate of exacerbations

    • Changes from baseline in annualized rate of exacerbations over 56 weeks after initiation of benralizumab.

    Time frame: Week 56

  2. percentage of patients with benralizumab discontinuation

    • Percentage of patients with benralizumab discontinuation at Week 24, 40 and 56 after initiation of benralizumab

    Time frame: Week 24,40,56

  3. Changes in Lung function

    Change from Baseline in Pre-bronchodilator Forced Expiratory Volume in 1 Second (pre-BD FEV1)

    Time frame: Weeks 8, 24 and 56 after initiation of benralizumab

  4. Changes in Lung function

    Change from Baseline in Forced Vital Capacity (FVC)

    Time frame: Weeks 8, 24 and 56 after initiation of benralizumab

  5. Changes in Lung function

    Change from Baseline in FEV1/FVC Ratio

    Time frame: Weeks 8, 24 and 56 after initiation of benralizumab

  6. Changes in Lung function

    Change from Baseline in Peak Expiratory Flow (PEF)

    Time frame: Weeks 8, 24 and 56 after initiation of benralizumab

  7. Changes in Lung function

    Change from Baseline in Post-bronchodilator FEV1/FVC Ratio

    Time frame: Weeks 8, 24 and 56 after initiation of benralizumab

  8. Change from Baseline in Six-item Asthma Control Questionnaire (ACQ-6) Score

    The ACQ-6 score ranges from 0 to 6, with higher scores indicating worse asthma control. Change from baseline is calculated as the post-baseline ACQ-6 score minus the baseline ACQ-6 score.

    Time frame: Weeks 1, 2, 8, 16, 24, 40 and 56 after initiation of benralizumab

  9. Percentage of Patients by Asthma Control Status Based on ACQ-6 Score

    The ACQ-6 score ranges from 0 to 6, with higher scores indicating worse asthma control. Patients are categorized as well controlled (ACQ-6 score ≤0.75), partially controlled (ACQ-6 score \>0.75 and \<1.5), or uncontrolled (ACQ-6 score ≥1.5).

    Time frame: Weeks 1, 2, 4, 8, 16, 24, 32, 40, 48 and 56 after initiation of benralizumab

  10. Percentage of Patients With Clinically Meaningful Improvement in ACQ-6 Score

    The ACQ-6 score ranges from 0 to 6, with higher scores indicating worse asthma control. Clinically meaningful improvement is defined as at least (≥) a 0.5-unit improvement in ACQ-6 score from baseline.

    Time frame: Weeks 1, 2, 4, 8, 16, 24, 40 and 56 after initiation of benralizumab

07

Study locations

36 of 36 sites recruiting
  • Research Site
    Anning, China
    Recruiting
  • Research Site
    Beijing, China
    Recruiting
  • Research Site
    Binzhou, China
    Recruiting
  • Research Site
    Changzhou, China
    Recruiting
  • Research Site
    Fenyang, China
    Recruiting
  • Research Site
    Guangdong, China
    Recruiting
  • Research Site
    Guangzhou, China
    Recruiting
  • Research Site
    Hangzhou, China
    Recruiting
  • Research Site
    Hefei, China
    Recruiting
  • Research Site
    Huzhou, China
    Recruiting
  • Research Site
    Jiaxing, China
    Recruiting
  • Research Site
    Jinan, China
    Recruiting
  • Research Site
    Jinhua, China
    Recruiting
  • Research Site
    Jining, China
    Recruiting
  • Research Site
    Jiyuan, China
    Recruiting
  • Research Site
    Kunshan, China
    Recruiting
  • Research Site
    Linyi, China
    Recruiting
  • Research Site
    Mianyang, China
    Recruiting
  • Research Site
    Nanbu, China
    Recruiting
  • Research Site
    Nanchang, China
    Recruiting
  • Research Site
    Nanjing, China
    Recruiting
  • Research Site
    Ningbo, China
    Recruiting
  • Research Site
    Shanghai, China
    Recruiting
  • Research Site
    Shanxi, China
    Recruiting
  • Research Site
    Shenzhen, China
    Recruiting
  • Research Site
    Shijiazhuang, China
    Recruiting
  • Research Site
    Suining, China
    Recruiting
  • Research Site
    Taiyuan, China
    Recruiting
  • Research Site
    Weifang, China
    Recruiting
  • Research Site
    Wuhan, China
    Recruiting
  • Research Site
    Wuxi, China
    Recruiting
  • Research Site
    Xi'an, China
    Recruiting
  • Research Site
    Xiamen, China
    Recruiting
  • Research Site
    Zhangjiagang, China
    Recruiting
  • Research Site
    Zhengzhou, China
    Recruiting
  • Research Site
    Zhenjiang, China
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA PhRMA Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2025 (actual). Primary completion is estimated for Jan 2028, 30 months after the start.

Of 90 industry-sponsored observational studies under Asthma, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 58. This study's planned 30 months is above that.

Counting every sponsor, half of 456 studies reached it within 36 months; a quarter within 18 and three quarters within 82.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 3, 2025
First posted
Mar 6, 2025
StartActual
Jul 11, 2025
Primary completionEst.
Jan 31, 2028
CompletionEst.
Jan 31, 2028
Last update
Nov 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added, 1 site removed
Show site
  • Research Site · Hefei, China
Show 1 removed
  • Research Site · Anhui, China
Nov 9, 2026
Primary completion
Jan 30, 2028→Jan 31, 2028
Nov 9, 2026
Study completion
Jan 30, 2028→Jan 31, 2028
Nov 9, 2026
Enrollment
1000→700
Nov 9, 2026
Eligibility
Minimum age none→12 Years; 2 inclusion criteria edited, 3 added; 3 exclusion criteria edited, 1 added; 3 criteria removed
What changed in the criteria
  • RemovedBlood EOS≥150/ul in the 3 months prior to or EOS≥300/ul in the 1 year prior to the time of signing the informed consent.
  • RemovedExclusion criteria
  • RemovedPatients with prior or ongoing treatment with benralizumab.
Inclusion criteria
  • EditedInclusion criteria -Patients are eligible to be included in the studyfor inclusion only if all of the following criteria applyare met:
  • EditedPatients must to be Aged ≥12 years old (inclusive) at the time of signing the informed consent form.
  • AddedFor the patients who had received benralizumab prior to enrolment, the interval between the Index date and the date of enrolment must <=4 weeks;
  • AddedACQ-6 score within 7 days prior to index date is required.
  • AddedPatients must have a current prescription for benralizumab with planned initiation of therapy.
Exclusion criteria
  • Edited-Patients should not enter the studybe enrolled if any of the following exclusion criteria are fulfilledmet:
  • EditedPatients currently participating in any other interventional clinical trial.
  • EditedKnown history of allergy or reaction to any component of the study treatment formulationbenralizumab.
  • AddedPregnant, breast-feeding or intending to become pregnant during the study period
Nov 9, 2026
Interventions
Added Drug: benralizumab; removed benralizumab
Nov 9, 2026
Primary outcomes
1 time frame changed, 1 description edited
What changed in the outcomes
  • Time frameasthma control questionnaireWeek 8 → Week 4
  • Descriptionasthma control questionnaire: how it is measured was reworded
Nov 9, 2026
Secondary outcomes
1 edited, 9 added, 1 removed
What changed in the outcomes
  • EditedchangesChanges in lungLung functionTime frame: week 8, 16 and 56 → Weeks 8, 24 and 56 after initiation of benralizumab
  • AddedRate of exacerbationsTime frame: Week 56
  • Addedpercentage of patients with benralizumab discontinuationTime frame: Week 24,40,56
  • AddedChanges in Lung functionTime frame: Weeks 8, 24 and 56 after initiation of benralizumab
  • AddedChanges in Lung functionTime frame: Weeks 8, 24 and 56 after initiation of benralizumab
  • AddedChanges in Lung functionTime frame: Weeks 8, 24 and 56 after initiation of benralizumab
  • AddedChanges in Lung functionTime frame: Weeks 8, 24 and 56 after initiation of benralizumab
  • AddedChange from Baseline in Six-item Asthma Control Questionnaire (ACQ-6) ScoreTime frame: Weeks 1, 2, 8, 16, 24, 40 and 56 after initiation of benralizumab
  • AddedPercentage of Patients by Asthma Control Status Based on ACQ-6 ScoreTime frame: Weeks 1, 2, 4, 8, 16, 24, 32, 40, 48 and 56 after initiation of benralizumab
  • AddedPercentage of Patients With Clinically Meaningful Improvement in ACQ-6 ScoreTime frame: Weeks 1, 2, 4, 8, 16, 24, 40 and 56 after initiation of benralizumab
  • Removedasthma control questionnaireTime frame: week 1, 2, 4, 8, 16, 24, 40 and 56.
Nov 9, 2026
Title
This is aA Multicentre, Single Arm, Non-interventional, Real-world Study to Assess Demographic Characteristics and Patient Reported Outcomes in China Patients With SEASevere Eosinophilic Asthma Treated With Benralizumab in China
Nov 9, 2026
Show all 1 update
  1. Nov 9, 2026
    1 site added, 1 site removed
    Show site
    • Research Site · Hefei, China
    Show 1 removed
    • Research Site · Anhui, China
    Primary completion Jan 30, 2028→Jan 31, 2028
    Study completion Jan 30, 2028→Jan 31, 2028
    Enrollment 1000→700
    Eligibility Minimum age none→12 Years; 2 inclusion criteria edited, 3 added; 3 exclusion criteria edited, 1 added; 3 criteria removed
    What changed in the criteria
    • RemovedBlood EOS≥150/ul in the 3 months prior to or EOS≥300/ul in the 1 year prior to the time of signing the informed consent.
    • RemovedExclusion criteria
    • RemovedPatients with prior or ongoing treatment with benralizumab.
    Inclusion criteria
    • EditedInclusion criteria -Patients are eligible to be included in the studyfor inclusion only if all of the following criteria applyare met:
    • EditedPatients must to be Aged ≥12 years old (inclusive) at the time of signing the informed consent form.
    • AddedFor the patients who had received benralizumab prior to enrolment, the interval between the Index date and the date of enrolment must <=4 weeks;
    • AddedACQ-6 score within 7 days prior to index date is required.
    • AddedPatients must have a current prescription for benralizumab with planned initiation of therapy.
    Exclusion criteria
    • Edited-Patients should not enter the studybe enrolled if any of the following exclusion criteria are fulfilledmet:
    • EditedPatients currently participating in any other interventional clinical trial.
    • EditedKnown history of allergy or reaction to any component of the study treatment formulationbenralizumab.
    • AddedPregnant, breast-feeding or intending to become pregnant during the study period
    Primary outcomes 1 time frame changed, 1 description edited
    What changed in the outcomes
    • Time frameasthma control questionnaireWeek 8 → Week 4
    • Descriptionasthma control questionnaire: how it is measured was reworded
    Secondary outcomes 1 edited, 9 added, 1 removed
    What changed in the outcomes
    • EditedchangesChanges in lungLung functionTime frame: week 8, 16 and 56 → Weeks 8, 24 and 56 after initiation of benralizumab
    • AddedRate of exacerbationsTime frame: Week 56
    • Addedpercentage of patients with benralizumab discontinuationTime frame: Week 24,40,56
    • AddedChanges in Lung functionTime frame: Weeks 8, 24 and 56 after initiation of benralizumab
    • AddedChanges in Lung functionTime frame: Weeks 8, 24 and 56 after initiation of benralizumab
    • AddedChanges in Lung functionTime frame: Weeks 8, 24 and 56 after initiation of benralizumab
    • AddedChanges in Lung functionTime frame: Weeks 8, 24 and 56 after initiation of benralizumab
    • AddedChange from Baseline in Six-item Asthma Control Questionnaire (ACQ-6) ScoreTime frame: Weeks 1, 2, 8, 16, 24, 40 and 56 after initiation of benralizumab
    • AddedPercentage of Patients by Asthma Control Status Based on ACQ-6 ScoreTime frame: Weeks 1, 2, 4, 8, 16, 24, 32, 40, 48 and 56 after initiation of benralizumab
    • AddedPercentage of Patients With Clinically Meaningful Improvement in ACQ-6 ScoreTime frame: Weeks 1, 2, 4, 8, 16, 24, 40 and 56 after initiation of benralizumab
    • Removedasthma control questionnaireTime frame: week 1, 2, 4, 8, 16, 24, 40 and 56.
    Interventions Added Drug: benralizumab; removed benralizumab
    Title This is aA Multicentre, Single Arm, Non-interventional, Real-world Study to Assess Demographic Characteristics and Patient Reported Outcomes in China Patients With SEASevere Eosinophilic Asthma Treated With Benralizumab in China
    + 3 other changes: index terms, verification date and conditions

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06862206
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Mar 6, 2025
Start date
Jul 11, 2025
Primary completion
Jan 31, 2028 (estimated)
Completion
Jan 31, 2028 (estimated)
Last update
Nov 9, 2026

Study contacts

AstraZeneca Clinical Study Information Center
Contact
information.center@astrazeneca.com
1-877-240-9479
chen wang, PhD
principal investigator · China-Japan Friendship Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion